Cargando…

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

BACKGROUND: According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in the price of evolocumab and its different methods of confirming clinical efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Yuansheng, Liu, Jinyu, Zhan, Xiaolian, Zhang, Yu, You, Ruxu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690971/ https://www.ncbi.nlm.nih.gov/pubmed/38041072 http://dx.doi.org/10.1186/s12962-023-00501-4

Ejemplares similares

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction
por: Zhao, Qi, et al.
Publicado: (2023)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain
por: Escobar-Cervantes, Carlos, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study
por: Blaha, V, et al.
Publicado: (2023)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
por: Alghamdi, Ahmed, et al.
Publicado: (2021)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial
por: Okada, Tomoaki, et al.
Publicado: (2022)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
por: Grégoire, Jean, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes
por: Blom, Dirk J., et al.
Publicado: (2020)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies
por: Stroes, Erik, et al.
Publicado: (2018)

Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis
por: Gao, Ge, et al.
Publicado: (2023)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients
por: Ou, Ziwei, et al.
Publicado: (2022)

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
por: You, Ruxu, et al.
Publicado: (2019)

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
por: Korthauer, Laura E., et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
por: Abdelmaseih, Ramy, et al.
Publicado: (2021)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
por: Li, Zhenxian, et al.
Publicado: (2023)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)
por: Makhmudova, Umidakhon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ihggqbsttd1buuci7n9afu57l2